Ask nr. 21972    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
5進行性核上性麻痺1

5. 進行性核上性麻痺 [臨床試験数:82,薬物数:107(DrugBank:36),標的遺伝子数:60,標的パスウェイ数:90
Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 82 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-000574-40-DE
(EUCTR)
24/04/200624/01/2006Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/ABrain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 100000 and an age-adjusted prevalence of 6.4 / 100000, PSP is as common as motor-neuron disease. The progression of PSP is rapid and the median survival after onset of symptoms is 5-10 years. Presently, there is no known effective symptomatic or neuroprotective therapy for PSP.Product Name: Coenzym Q10 Nanodispersion
Product Code: ASK Nr. 21972
INN or Proposed INN: Ubidecarenon
Other descriptive name: Coenzym Q10, Ubiquinon, Ubichinon
Kompetenznetz Parkinson e.V.NULLNot RecruitingFemale: yes
Male: yes
30Germany